Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as $14.92 and last traded at $15.17, with a volume of 409413 shares changing hands. The stock had previously closed at $15.75.
Analyst Ratings Changes
A number of brokerages have weighed in on TNDM. Wells Fargo & Company cut their target price on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating for the company in a research report on Thursday, May 1st. Stifel Nicolaus decreased their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Mizuho initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target on the stock. Wall Street Zen downgraded shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Finally, Canaccord Genuity Group lifted their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $32.71.
Read Our Latest Stock Analysis on Tandem Diabetes Care
Tandem Diabetes Care Stock Down 4.7%
The business has a 50-day simple moving average of $20.29 and a two-hundred day simple moving average of $24.31. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -5.37 and a beta of 1.48. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.81 and a current ratio of 2.30.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The business had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period in the previous year, the company posted ($0.65) earnings per share. Tandem Diabetes Care's revenue was up 22.3% on a year-over-year basis. As a group, equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.
Hedge Funds Weigh In On Tandem Diabetes Care
A number of hedge funds have recently added to or reduced their stakes in the business. Envestnet Portfolio Solutions Inc. increased its stake in Tandem Diabetes Care by 22.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock valued at $236,000 after buying an additional 1,184 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Tandem Diabetes Care by 17.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 72,752 shares of the medical device company's stock valued at $1,394,000 after purchasing an additional 11,048 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Tandem Diabetes Care by 27.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 38,450 shares of the medical device company's stock valued at $737,000 after purchasing an additional 8,210 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Tandem Diabetes Care by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Tandem Diabetes Care by 763.3% during the 1st quarter. GAMMA Investing LLC now owns 42,190 shares of the medical device company's stock valued at $808,000 after purchasing an additional 37,303 shares in the last quarter.
About Tandem Diabetes Care
(
Get Free Report)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
